YES1 amplification confers trastuzumab–emtansine (T-DM1) resistance in HER2-positive cancer

BACKGROUND: Trastuzumab–emtansine (T-DM1), one of the most potent HER2-targeted drugs, shows impressive efficacy in patients with HER2-positive breast cancers. However, resistance inevitably occurs and becomes a critical clinical problem. METHODS: We modelled the development of acquired resistance b...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lei, Wang, Quanren, Xu, Piaopiao, Fu, Li, Li, Yun, Fu, Haoyu, Quan, Haitian, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494777/
https://www.ncbi.nlm.nih.gov/pubmed/32572172
http://dx.doi.org/10.1038/s41416-020-0952-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494777/
https://www.ncbi.nlm.nih.gov/pubmed/32572172
http://dx.doi.org/10.1038/s41416-020-0952-1

Ejemplares similares